Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label study of pimecrolimus 1% cream for seborrhoeic dermatitis
2006-000336-28Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pimecrolimus in seborrheic dermatitis (SD), sponsored by Novartis. Primary endpoints: Safety and tolerability and Non-melanoma skin cancer incidence. Started Apr 2006; status: completed.
02
Drugs
pimecrolimus
03
Conditions
seborrheic dermatitis (SD)
Beyond the preview
Go deeper on 2006-000336-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000336-28.